A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients.
Financing follows Torres's CrossBridge Bio acquisition by Eli Lilly and supports translation of ARTAN Bio's programmable approach to mutation-driven aging biology. ST. PETERSBURG, ...
Morning Overview on MSN
Mutations behind blood cancers may help ignite Alzheimer’s in the brain
Mutations that accumulate in blood cells with age and raise the risk of leukemia and lymphoma can also colonize the brain’s ...
Company will showcase new assay at the upcoming San Antonio Breast Cancer Symposium While mutations in the ESR1 gene are exceedingly rare in cancer patients prior to treatment, the use of endocrine ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...
A study published in Nature Communications revealed a new antisense oligonucleotide (ASO) therapy applicable to the W1282X mutation of the cystic fibrosis transmembrane conductance regulator gene ...
ARTAN Bio has developed a novel engineered suppressor tRNA system (ARTAN-102) designed to selectively recognize disease-causing nonsense codons and restore normal protein translation. Unlike ...
Researchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results